MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Metagenomi Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$0.81+0.03 (+3.55%)
Close on Oct 19, 2026
- Market cap
- $30.57M
- P/E (TTM)
- –
- Dividend yield
- –
Metagenomi Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Metagenomi Therapeutics | Industry median |
|---|---|---|
| Market Cap | $30.67M | $166.30M |
| Enterprise Value | -$90.03M | $88.19M |
| PB Ratio | 0.27 | 2.03 |
| P/TBV Ratio | 0.27 | 2.29 |
Income (trailing twelve months)
| Measure | Metagenomi Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$100.57M | -$21.40M |
| Pretax Income | -$93.65M | -$14.34M |
| Net Income | -$93.46M | -$22.46M |
| EBITDA | -$100.57M | -$16.91M |
| EPS (Diluted) | -$2.49 | -$0.83 |
Returns
| Measure | Metagenomi Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -60.6% | -53.2% |
| Return on Assets (ROA) | -41.9% | -40.9% |
| Return on Capital Employed (ROCE) | -68.8% | -38.1% |
Balance sheet
| Measure | Metagenomi Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $120.70M | $61.43M |
| Net Cash (Debt) | $120.70M | $15.35M |
| Net Cash Per Share | $3.20 | $0.66 |
| Equity (Book Value) | $112.57M | $49.09M |
| Book Value Per Share | $2.98 | $1.37 |
| Tangible Book Value | $112.57M | $23.52M |
| Working Capital | $96.84M | $76.81M |
Financial position
| Measure | Metagenomi Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 4.50 | 3.34 |
| Quick Ratio | 4.37 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Metagenomi Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$85.49M | -$12.35M |
| Capital Expenditures | -$309.00K | -$1.08M |
| Free Cash Flow | -$85.80M | -$20.22M |
| FCF Per Share | -$2.27 | -$0.42 |
Efficiency
| Measure | Metagenomi Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$785.40K | -$703.34K |
| Employee Count | 119 | 74 |
Dividends and yields
| Measure | Metagenomi Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -304.8% | -23.3% |
| FCF Yield | -279.8% | -8.72% |
Shares
| Measure | Metagenomi Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 37,777,100 | 58,127,000 |
| Shares Change (YoY) | 1.22% | 10.9% |
| Shares Change (QoQ) | 0.35% | 0.54% |
| Float | 33,833,700 | 49,136,700 |
| Shares Held by Insiders | 10.4% | 11.6% |
| Shares Held by Institutions | 16.6% | 59.4% |
Taxes
| Measure | Metagenomi Therapeutics | Industry median |
|---|---|---|
| Income Tax | -$190.00K | $79.87K |
Scores
| Measure | Metagenomi Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -3.85 | -0.22 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Metagenomi Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.